On Friday, the New England Health Institute (NEHI), outlined six “Priorities for Action” to help steer the solution to better medication adherence in the US.
By
Clark Herman
| Published: August 1, 2013
On Friday, the New England Health Institute (NEHI), outlined six “Priorities for Action” to help steer the solution to better medication adherence in the US. These priorities signal public and private policymakers alike to improve the way patients take their medication.
In 2009, NEHI published research which found that people with poor medication adherence, either by not taking their medication accordingly or not at all, cost the US health care system $290 billion annually. In addition to this research, the Congressional Budget Office published its own study describing the beneficial impact of adherence to therapy; with a projected 5% increase from exposure of Medicare to cover drugs would lead to a 1% decrease in the programs medical and hospital spending.
NEHI’s new report, which resulted from a series of roundtables on adherence in 2012, focuses on the following six points in developing a comprehensive, system-wide solution:
For more information, visit NEHI’s website: http://www.nehi.net
Key Findings of the NIAGARA and HIMALAYA Trials
November 8th 2024In this episode of the Pharmaceutical Executive podcast, Shubh Goel, head of immuno-oncology, gastrointestinal tumors, US oncology business unit, AstraZeneca, discusses the findings of the NIAGARA trial in bladder cancer and the significance of the five-year overall survival data from the HIMALAYA trial, particularly the long-term efficacy of the STRIDE regimen for unresectable liver cancer.
Fake Weight Loss Drugs: Growing Threat to Consumer Health
October 25th 2024In this episode of the Pharmaceutical Executive podcast, UpScriptHealth's Peter Ax, Founder and CEO, and George Jones, Chief Operations Officer, discuss the issue of counterfeit weight loss drugs, the potential health risks associated with them, increasing access to legitimate weight loss medications and more.